A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Oral Ozanimod As Maintenance Therapy For Moderately To Severely Active Crohn's Disease
Whereas, the Federal Laboratory and the Collaborating Party are entering into this Agreement for the mutual benefit of each Party. This joint research project will benefit the Collaborating Party by accomplishing its mission to promote and support the advancement of military medicine and specifically military medical research. The project will benefit the Federal Laboratory by providing valuable research experience for the medical residents of the teaching program involved. In addition, patients at SAMMC with moderately to severely active Crohn's Disease may benefit through potential use of oral Ozanimod.